Precision Medicine
Novaseq 6000
offers high throughput whole genome, exome and targeted gene sequencing. 3000 GB per run. Maximum read length -250bp
Illumina Nextseq2000
offers high throughput whole genome, exome and targeted gene sequencing. 360 GB per run. approx. Maximum read length -151bp
MiSeq
offers wide range of options – 300Mb to 15Gb per run. Read lengths from 36bp to 2x300bp
Novaseq 6000
offers high throughput whole genome, exome and targeted gene sequencing. 3000 GB per run. Maximum read length -250bp
Illumina Nextseq2000
offers high throughput whole genome, exome and targeted gene sequencing. 360 GB per run. approx. Maximum read length -151bp
MiSeq
offers wide range of options – 300Mb to 15Gb per run. Read lengths from 36bp to 2x300bp
Harnessing Next-Generation Sequencing for Precision Oncology
At Innovate Life Sciences in collaboration with 4basecare, we are at the forefront of transforming
cancer care through precision medicine. Our commitment lies in making advanced genomic profiling
technologies like next-generation sequencing (NGS) accessible to a wider audience of cancer
patients. Positioned uniquely at the crossroads of drug development and patient care, we strive to
turn the vision of personalized healthcare into a reality for everyone.
Join us as we lead the way in delivering more personalized, effective cancer treatments
We Bring Biomarker Expertise You Can Depend On
Empowering Precision Oncology with Next-Generation Sequencing
Next-Generation Sequencing (NGS) is a cornerstone in selecting precise medicines for the right , driving the future of personalized cancertreatment. This validated approach enhances, accelerates, and refines the selection of the most suitable cancer treatments and clinical trials with unparalleled accuracy.
By analysing DNA or RNA sequences, NGS uncovers genetic variations that are crucial for
understanding disease mechanisms and other biological conditions.
Despite its proven effectiveness and recommendations from clinical guidelines, NGS testing is not as widely used as it could be.
This is notably true in the realm of targeted molecular therapies for late-stage metastatic non-small cell lung cancer (mNSCLC), one of the cancers most frequently analyzed with NGS. Yet, less than 50% of mNSCLC patients receive NGS as part of their diagnostic and treatment regimen, highlighting a significant gap in harnessing this technology’s full potential.
The underutilization is often attributed to perceived challenges in adopting NGS, underscoring the need for increased awareness and integration of this technology into cancer care to truly transform patient outcomes.
ILS will help You Overcome the Perceived Challenges of NGS
Lack of Clarity on the Clinical Utility of NGS
Shining Light on Appropriate Use of NGS
We know that it’s not always clear when NGS should be implemented in cancer care and which patients can benefit from it the most. There are certain malignancies for which the use of NGS is less established, but growing evidence suggests that advanced genomic testing could be an appropriate option, particularly in the clinical trial setting.
We have an integrated NGS testing options available for solid tumors and hematologic malignancies, including:-
Breast Cancer
Pancreatic Cancer
Ovarian Cancer
Cervical Cancer
Bladder Cancer
Thyroid Cancer
When you encounter patients who are living with any of these conditions, we’re here to help you identify the optimal treatment paths through our comprehensive NGS offerings.
Pan-Cancer
TARGT First
Affordable Biomarker Testing for Everyone
Highly affordable and targeted pan-solid cancer gene panel, featuring 72 of the most commonly mutated genes backed by substantial evidence linked to cancer
Focussed gene panel with biomarkers identified for solid tumors, for which there are NCCN and FDA-approved therapeutic options
Furthermore, TARGT First offers an integrated NGS method combining solid and liquid biopsies. This dual approach maximizes insights by leveraging strengths from both types of samples. It addresses the limitations of each method, contributing to a comprehensive understanding of the disease’s genomic characteristics
Target Absolute Pro
Single tumor biopsy analyzed by advanced NGS technology
Integrated NGS analysis of Tissue (Solid biopsy), ctDNA (Liquid biopsy), and Whole blood (gDNA) allows identifying true somatic mutations and queries both tissue DNA/RNA and ctDNA
Gain Optimal Disease Resolution leading to better clinical decision-making.
Only all-in-one test that identifies all treatment options in one comprehensive, easy-to-read report
Collateral
If you need support determining which tests are most relevant for your patients, our team of experts is ready to explain the practical applications of our testing options.
Our Clear and Concise Reports Can Help Guide Your Treatment Recommendations
NGS reports can be hard to understand, often comprised of multiple pages of data without clear insights or direction. That’s why we continue to improve our reports to include actionable insights, including likely response to therapy, guidelines-based treatment recommendations and suggestions for nearby clinical trials.
- References
Cobain EF, Wu YM, Vats P, et al. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. JAMA Oncol. 2021;7(4):525-533. 2. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491-1505. 3. Robert NJ, Nwokeji ED, Espirito JL, et al. Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices. J. Clin. Oncol. 2021;39(15):9004-9004. 4. Kluk MJ, Lindsley RC, Aster JC, et al. Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. J Mol Diagn. 2016;18(4):507-515.
Cobain EF, Wu YM, Vats P, et al. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. JAMA Oncol. 2021;7(4):525-533. 2. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491-1505. 3. Robert NJ, Nwokeji ED, Espirito JL, et al. Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices. J. Clin. Oncol. 2021;39(15):9004-9004. 4. Kluk MJ, Lindsley RC, Aster JC, et al. Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. J Mol Diagn. 2016;18(4):507-515.
Precision Cardiology
Our experts at ILS have meticulously crafted the cardiovascular genetic test menu to provide an extensive array of options focused on heart and vascular health.
Inherited heart diseases, a diverse group with significant genetic factors and notable prevalence, stand as our focal point.
Through genetic testing, we’re able to pinpoint those at elevated risk for cardiovascular issues, significantly enhancing diagnosis, treatment plans, and symptom management.
- Aortopathies
- Arrhythmias
- Arrhythmogenic Right Ventricular Cardiomyopathy
- Cardiac Arrest
- Cardiomyopathy
- Comprehensive Cardiology
- Congenital Heart Disease
- Disorders of Fatty Acid Oxidation
- Ehlers-Danlos Syndrome
- Fabry Disease
- Hereditary Hemorrhagic Telangiectasia
- Hypercholesterolemia
- Left Ventricular Noncompaction
- Loeys-Dietz Syndrome
- Marfan Syndrome
- Pulmonary Hypertension
- Aortopathies
- Arrhythmias
- Arrhythmogenic Right Ventricular Cardiomyopathy
- Cardiac Arrest
- Cardiomyopathy
- Comprehensive Cardiology
- Congenital Heart Disease
- Disorders of Fatty Acid Oxidation
- Ehlers-Danlos Syndrome
- Fabry Disease
- Hereditary Hemorrhagic Telangiectasia
- Hypercholesterolemia
- Left Ventricular Noncompaction
- Loeys-Dietz Syndrome
- Marfan Syndrome
- Pulmonary Hypertension
If you need support determining which tests are most relevant for your patients, our team of experts is ready to explain the practical applications of our testing options
Rare Diseases
Treating physicians often face significant challenges with rare diseases due to their complexity and the lack of standardized diagnostic and therapeutic measures in routine clinical practice. While causal treatments may not yet be available for every patient, achieving a definitive diagnosis can put an end to the often years-long search for the cause of their condition.
At ILS, we provide actionable insights through Comprehensive Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) and reporting diagnostics for rare Mendelian disorders as per ACMG/AMP guidelines.
Collaborating closely with researchers and clinicians, we advocate for the clinical application of Next Generation Sequencing (NGS). This advanced technology has shown a remarkable diagnostic yield of up to 48% for individuals undergoing the arduous journey known as the “Diagnostic Odyssey.
- Our test portfolio include focussed exome based CNV profiling targeting the following conditions
- Androgen Insensitivity Syndrome
- Bardet-Biedl Syndrome
- Ciliopathies
- Combined Pituitary Hormone Deficiency
- Congenital Adrenal Hyperplasia
- Cystic Fibrosis
- Female Infertility
- Fragile X Syndrome
- Fraser Syndrome
- Galactosemia
- Hypogonadism
- Hypospadias
- Joubert and Meckel-Gruber Syndromes
- Male Infertility
- Premature Ovarian Failure (POF)
- Premature Ovarian Failure (POF1)
- Y Chromosome Deletion
If you need support determining which tests are most relevant for your patients, our team of experts is ready to explain the practical applications of our testing options
